| Literature DB >> 32656623 |
Zahra Alijani-Ghazyani1, Reza Sabzevari1, Amaneh Mohammadi Roushandeh1,2, Ali Jahanian-Najafabadi3, Fatemeh Amiri4, Mehryar Habibi Roudkenar5.
Abstract
Myocardial infarction (MI) is a leading cause of death worldwide and requires development of efficient therapeutic strategies . Mesenchymal stem cells (MSCs) -based therapy of MI has been promising but inefficient due to undesirable microenvironment of the infarct tissue. Hence, the current study was conducted to fortify MSCs against the unfavorable microenvironment of infarct tissue via overexpression of Lipocalin 2 (Lcn2) as a cytoprotective factor. The engineered cells (Lcn2-MSCs) were transplanted to infarcted heart of a rat model of MI. According to our findings, Lcn2 overexpression resulted in increased MSCs survival in the MI tissue (p < 0.05) compared to non-engineered cells. Furthermore, the infusion of Lcn2-MSCs mitigated Left ventricle (LV) remodeling, decreased fibrosis (p < 0.0001), and reduced apoptotic death of the LVs' cells (p < 0.0001) compared to the control. Our findings suggest a potential novel therapeutic strategy for MI, however, further investigations such as safety and efficacy assessments in large animals followed by clinical trials are required.Entities:
Keywords: Apoptosis; Exogenous expression; Lipocalin 2; Mesenchymal stem cells; Myocardial infarction
Mesh:
Substances:
Year: 2020 PMID: 32656623 DOI: 10.1007/s12015-020-10007-8
Source DB: PubMed Journal: Stem Cell Rev Rep ISSN: 2629-3277 Impact factor: 5.739